Ronak Exim Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Ronak Exim Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $11.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ronak Exim Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $11.7M Trade | TransData Nexus

Ronak Exim Private Limited

Indian Pharmaceutical Exporter · Respiratory & OTC Specialist · $11.7M Total Trade · DGFT Verified

Ronak Exim Private Limited is an Indian pharmaceutical exporter with a total trade value of $11.7M across 4 products in 4 therapeutic categories. Based on 746 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Caffeine ($6.4M), Gentamicin ($5.0M), Mebendazole ($188.4K).

Ronak Exim Private Limited — Export Portfolio & Destination Treemap

Ronak Exim Private Limited pharmaceutical export portfolio — 4 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Ronak Exim Private Limited? — Company Overview & Market Position

Ronak Exim Private Limited, established on July 5, 2006, is a privately held pharmaceutical company headquartered in Vadodara, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U51109GJ2006PTC048622. With an authorized and paid-up capital of ₹2.5 million, Ronak Exim has grown to become one of India's fastest-growing pharmaceutical exporters.

The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Their product portfolio spans various therapeutic categories, with a significant focus on respiratory and over-the-counter (OTC) medications, antibiotics, and antimalarial and antiparasitic drugs. Ronak Exim markets over 500 products under its own brand name, with manufacturing outsourced to facilities that comply with international quality standards.

What Does Ronak Exim Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Caffeine$6.4M 2

Product Portfolio — Top 4 by Export Value

Ronak Exim Private Limited exports 4 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Caffeine	Respiratory & OTC	$6.4M	457	4.6%	3
2	Gentamicin	Antibiotics	$5.0M	236	6.1%	4
3	Mebendazole	Antimalarial & Antiparasitic	$188.4K	45	1.4%	12
4	Paracetamol Caffeine	Combination Drugs	$90.0K	8	6.5%	3

Ronak Exim Private Limited exports 4 pharmaceutical products across 4 therapeutic categories with a total export value of $11.7M. The top category is Respiratory & OTC (54.5% of portfolio), followed by Antibiotics (43.1%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Ronak Exim Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Ronak Exim Private Limited operates manufacturing facilities that have been audited and approved by various international regulatory agencies, including WHO-GMP, National Drug Authority Uganda, Kenya, Yemen, Ethiopia, Congo, Ghana, Zimbabwe (MCAZ), Cambodia, Vietnam, Malawi, Namibia, Nigeria, Ivory Coast, Philippines, and Peru.

3Key Leadership

The leadership team at Ronak Exim Private Limited comprises:

Ronakali Saifuddin Dholkawala: Managing Director
Nayabali Saifuddin Dholkawala: Whole-Time Director
Ahmedali Saifuddin Dholkawala: Director
Asgarali Saifuddin Dholkawala: Director

These individuals have been instrumental in steering the company towards its current position in the pharmaceutical export market.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Ronak Exim Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Ronak Exim Private Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals and regulatory filings in these regions, facilitating market access for its pharmaceutical products. Specific details regarding the number of approved Abbreviated New Drug Applications (ANDAs), Drug Master Files (DMFs), and inspection histories are not publicly disclosed.

2Emerging Markets

The company has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. Ronak Exim's products have been prequalified by the World Health Organization (WHO), enabling access to these regions. This prequalification ensures that their products meet international quality standards, facilitating smoother entry into these markets.

3Geographic Strategy

Ronak Exim Private Limited has strategically diversified its market presence across various regions, including Africa, South Asia, and East Asia. This diversification mitigates concentration risk and positions the company to leverage growth opportunities in multiple markets. The company's strategic direction focuses on expanding its global footprint while maintaining a strong presence in existing markets.

Ronak Exim Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Ronak Exim Private Limited's FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly available. The company has established a presence in regulated markets, indicating compliance with international standards.

2WHO & EU GMP

Ronak Exim's manufacturing facilities have been audited and approved by various international regulatory agencies, including WHO-GMP. This certification underscores the company's commitment to maintaining high-quality manufacturing standards.

3CDSCO & Indian Regulatory

Ronak Exim Private Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained approvals from state drug controllers. The company has also secured export No Objection Certificates (NOCs), facilitating the export of its pharmaceutical products.

Recent Regulatory Actions

Ronak Exim Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Ronak Exim Private Limited operates in a competitive pharmaceutical export market, with several companies offering similar product portfolios. While specific market share comparisons are not publicly available, the company's focus on high-quality products and adherence to international standards position it favorably among competitors.

2Key Differentiators

Ronak Exim's key differentiators include its extensive product portfolio of over 500 pharmaceutical formulations, commitment to high-quality manufacturing standards, and a strong presence in both regulated and emerging markets. The company's focus on customer service and reliability further distinguishes it in the market.

3Strategic Position

Ronak Exim Private Limited's current strategic direction emphasizes the expansion of its generics portfolio, with a focus on high-quality, affordable pharmaceutical formulations. The company's future outlook includes further diversification into specialty products and biosimilars, aiming to enhance its position in the global pharmaceutical market.

Buyer Due Diligence Brief — Evaluating Ronak Exim Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Ronak Exim Private Limited has a strong track record in the pharmaceutical export sector, with a total export value of $11.7 million USD and 746 shipments across 4 therapeutic categories from 2022 to 2026. The company's portfolio concentration is notable, with its top 5 products accounting for 100% of its exports. This indicates a focused approach to product offerings and market strategy.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and compliance:

FDA Approval: Confirm through the FDA's official website or contact the company directly.
WHO-GMP Certification: Verify via the World Health Organization's official website or request documentation from the company.
EU GMP Certification: Check with the European Medicines Agency or the company for certification details.

Frequently Asked Questions — Ronak Exim Private Limited

How many pharmaceutical products does Ronak Exim Private Limited export from India?

Ronak Exim Private Limited exports 4 pharmaceutical products across 4 therapeutic categories. The top exports are Caffeine ($6.4M), Gentamicin ($5.0M), Mebendazole ($188.4K), Paracetamol Caffeine ($90.0K). Total export value is $11.7M.

What is Ronak Exim Private Limited's total pharmaceutical export value?

Ronak Exim Private Limited's total pharmaceutical export value is $11.7M, based on 746 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Ronak Exim Private Limited cover?

Ronak Exim Private Limited exports across 4 therapeutic categories. The largest are Respiratory & OTC (54.5%, 1 products), Antibiotics (43.1%, 1 products), Antimalarial & Antiparasitic (1.6%, 1 products).

Get Full Ronak Exim Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.